Biogen resurrects Alzheimer's drug; shares jump 35per cent

REUTERS: Biogen Inc revealed surprise plans to seek U.S. regulatory approval for its Alzheimer's treatment aducanumab on Tuesday, saying new analysis of clinical trials showed promise, just months after it had shelved two studies.

There are no current approved therapies for reversing the decline of Alzheimer's and any successful new treatment is likely to garner billions in sales. Alzheimer's makes up 60-70per cent of an estimated 50 million cases of dementia globally. "The viability of such a filing is unknown, given the mixed results - in our view, Biogen is somewhat desperate for growth drivers...so a change in narrative is badly needed."

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Biogen to seek US approval for Alzheimer's drug; shares jump 21per centBiogen Inc is planning to file for U.S. regulatory approval for its Alzheimer's treatment aducanumab after fresh analysis of its clinical trial ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »

Biogen to seek US approval for Alzheimer's drug; shares jump 21per centBiogen Inc is planning to file for U.S. regulatory approval for its Alzheimer's treatment aducanumab after fresh analysis of its clinical trial ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »

Love For All Seasons concert aims to raise funds for Alzheimer's Disease AssociationSINGAPORE — Love For All Seasons, a charity concert organised by private banker Angela Saik in support of the Azhelmer’s Disease Association, will be back for a second straight year at the Gateway Theatre on Saturday (26 October).
Source: YahooSG - 🏆 3. / 71 Read more »